Health

New treatment destroys head and neck cancer tumours in trial

A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered.

In a landmark trial, a cocktail of immunotherapy medications harnessed patients’ immune systems to kill their own cancer cells and prompted “a positive trend in survival”, according to researchers at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.

One patient, who was expected to die four years ago, spoke of the “amazing” moment nurses called him weeks after he joined the study to say his tumour had “completely disappeared”. The 77-year-old grandfather is now cancer-free and spent last week on a cruise with his wife.

Scientists found the combination of nivolumab and ipilimumab medications led to a reduction in the size of tumours in terminally ill head and neck cancer patients. In some, their cancer vanished altogether, with doctors stunned to find no detectable sign of disease.

Combining the two immunotherapy drugs could prove an effective new weapon against several forms of advanced cancer, experts believe. Results from other trials of the drug combination have previously suggested similar benefits for terminally ill kidney, skin and bowel cancer patients.

As well as boosting the long-term survival chances of patients, scientists said, the immunotherapy treatment also triggered far fewer side-effects compared with the often gruelling nature of “extreme” chemotherapy, which is the standard treatment offered to many patients with advanced cancer.

The results from the phase 3 trial, involving almost 1,000 dying head and neck cancer patients, were early and not statistically significant but were still “clinically meaningful”, the ICR said, with some patients living months or years longer and suffering fewer side effects.

“These are promising results,” Prof Kristian Helin, the ICR chief executive, told the Guardian. “Immunotherapies are kinder, smarter treatments that can bring significant benefits to patients.”

About 12,000 people in the UK are diagnosed with head and neck cancer every year and many will be diagnosed at advanced stages. There is an urgent need for better, kinder treatments for these patients that can keep them alive longer than the current standard of care.

When Barry Ambrose, 77, from Bury St Edmunds, was diagnosed with throat cancer in 2017, he was told that it had already spread to his lungs – and that hospital palliative care was his only option.

But in a turn of events that saved his life, Ambrose was offered the chance to join the new study. “When I was told about the trial … I didn’t hesitate to join – what did I have to lose? It turned out to be a lifeline.

“Although I had to make biweekly trips from Suffolk to the hospital for the treatment, I had virtually no side-effects and was able to carry on as normal doing the things I love: sailing, cycling, and spending time with my family.”

Within about eight weeks of starting the treatment, scans revealed the tumour in his throat had been eradicated.

“When the research nurses called to tell me that, after two months, the tumour in my throat had completely disappeared, it was an amazing moment,” said Ambrose. “While there was still disease in my lungs at that point, the effect was staggering.”

He later underwent chemotherapy, followed by surgery. He currently has no evidence of disease.

“The treatment I’ve received at the Royal Marsden has been second to none and I’m so fortunate they’ve continued to find treatment that works for me – they’re the gift that keeps on giving,” said Ambrose. Last week he enjoyed a cruise off the coast of the UK with his wife, Sue.

The results of the trial show the immunotherapy combination enjoyed a particularly high success rate in a group of patients whose tumours had high levels of an immune marker called PD-L1.

Survival rates in those with high levels of PD-L1 who received the immunotherapy cocktail were the highest ever reported in a firstline therapy trial of relapsed or metastatic head and neck cancer.

These patients lived an average of three months longer than those having chemotherapy. The median overall survival for these patients was 17.6 months, the highest average ever reported in this group of patients.

Researchers said they hoped future findings from the CheckMate 651 trial, funded by Bristol Myers Squibb, will show further benefits of the therapy in patients with advanced head and neck cancers.

“Despite the lack of statistical significance, these results are clinically meaningful,” said Prof Kevin Harrington, professor of biological cancer therapies at the ICR and consultant clinical oncologist at the Royal Marsden, who led the CheckMate 651 trial. “We will need to do longer follow-up to see whether we can demonstrate a survival benefit across all patients in the trial.”

Health

WHO appoints Ihekweazu as ED Health Emergencies Programme

Nigerian epidemiologist, Dr. Chikwe Ihekweazu has been appointed as the Executive Director of the World Health Organisation’s (WHO) Health Emergencies Programme. This appointment marks a significant milestone, placing a Nigerian at the helm of WHO’s largest department responsible for coordinating global responses to health emergencies.

Prior to this role, Ihekweazu served as WHO’s Assistant Director-General for Health Emergency Intelligence and Surveillance Systems. He is also widely recognised for his transformative leadership as the founding Director-General of the Nigeria Centre for Disease Control (NCDC), where he led the agency from 2016 to 2021, establishing it as one of Africa’s leading public health institutions.

In February 2025, Ihekweazu was appointed Acting Regional Director for WHO Africa, succeeding Dr. Matshidiso Moeti. His tenure during this transition period received commendations for his leadership until the nomination of Professor Mohamed Yakub Janabi as the next Regional Director.

Ihekweazu’s appointment comes at a critical time as the world faces numerous health challenges, including emerging infectious diseases, the impacts of climate change, and strained health financing. His extensive background in public health and epidemiology is expected to bolster WHO’s capacity to respond effectively to global health emergencies.

The Federal Ministry of Health and Social Welfare celebrated his appointment, describing it as a proud moment for Nigeria. Coordinating Minister Prof. Muhammad Ali Pate hailed Ihekweazu as ‘the right choice at the right time’, praising his bold and compassionate leadership as crucial for navigating the complexities of the global health landscape.

Ihekweazu succeeds Dr. Mike Ryan, who led the Health Emergencies Programme through critical events, including the COVID-19 pandemic. In his new role, Ihekweazu will oversee WHO’s preparedness, response, and mitigation efforts for global health emergencies, ensuring that the organization remains agile and effective in safeguarding public health.

His appointment is part of a broader leadership restructuring within WHO, aimed at enhancing its operational efficiency and responsiveness to global health challenges.

Ihekweazu’s career spans senior roles at the South African National Institute for Communicable Diseases, the UK’s Health Protection Agency, and Germany’s Robert Koch Institute. He holds a Master of Public Health from Heinrich Heine University in Düsseldorf, Germany, and is an alumnus of the European Programme for Intervention Epidemiology Training.

His leadership is anticipated to bring renewed focus to strengthening health systems, improving surveillance, and fostering international collaboration to address current and emerging health threats.

Ihekweazu’s appointment not only underscores his exceptional contributions to global health but also highlights Africa’s growing influence in shaping international health policy and governance.

Health

Bayelsa records 98% immunisation coverage

Bayelsa has recorded a 98 per cent coverage in the first round of the 2025 National Immunisation Plus Days (NIPDs) programme conducted from the May 3 to May 6.

Mr Lawrence Ewhrudjakpo, deputy governor of the state, disclosed this during a meeting of the state’s taskforce on immunisation in Yenagoa on Wednesday.

He said that the government’s ultimate target was to achieve 100 per cent coverage in subsequent immunisation campaigns.

Ewhrudjakpo lauded the WHO, UNICEF, the Ministry of Health and other critical stakeholders for the feat achieved so far.

He, however, urged the partners not to rest on their oars as much still have to be done to achieve its target of 100 per cent immunization coverage.

He underscored the need for early preparations ahead of the second round of 2025 NIPDs scheduled for July.

The deputy governor assured the partners that funds for the programme would be released not later than two weeks to its commencement.

He directed all council chairmen to flag-off the second round of the 2025 NIPDs programme at any community other than their respective local government headquarters.

The deputy governor urged the chairmen to meet with the traditional rulers, school proprietors, and religious leaders in their areas to sensitise them on the importance of immunisation.

He also called parents, schools and churches to allow children to participate in the immunisation programme.

”The state government is serious about enforcing its public health law and executive order on compulsory immunisation.

“We have taken our immunisation coverage up to 98 per cent. But we want to take it to 100 per cent this time around, and that is why we have convened this meeting.

“We are also going to make an upward review of the logistics to reflect the present economic realities in the country,” he said.

Presentations by Dr Marcus Oluwadare of the WHO, and Dr Gbanaibulou Orukari, Director of Disease Control, Bayelsa State Primary Healthcare Board, revealed that area councils scored high percentage in the coverage.

They, however, identified poor workload rationalisation, data falsification and lack of commitment on the part of some personnel.

According to Oluwadare, we commend the Deputy Governor of the state for flagging off the NIPDs and chairing all the state ERMs in spite of his tight schedule.

“Bayelsa State was the only state to have full complements of her stakeholders in attendance during the April NIPDs in the whole of Nigeria,” he said.

Health

NCDC records 832 Lassa fever, Mpox cases, 135 deaths

The Nigeria Centre for Disease Control and Prevention (NCDC) has confirmed the country has recorded 832 confirmed cases of Lassa fever and Mpox.

Speaking during a press briefing on Friday in Abuja, the agency’s Director General, Dr. Jide Idris, revealed that 132 fatalities were recorded from Lassa fever and three from Mpox.

While acknowledging a recent decline in Lassa fever infections during epidemiological week 16 (ending April 20, 2025), he warned that the overall risk remains high, particularly in endemic regions.

“Cumulatively, as of week 16, Nigeria has reported 4,253 suspected cases of Lassa fever, 696 confirmed cases, and 132 deaths, resulting in a case fatality rate of 19.0 percent,” he stated.

Dr. Idris attributed recent improvements to intensified surveillance, treatment efforts, and enhanced community engagement. He emphasized, however, the continued need for vigilance and collaboration to sustain progress.

Regarding Mpox, the NCDC boss disclosed that three deaths have been recorded in 2025—two in Abia and Ebonyi States in week 10, and one recently in Rivers State involving a patient co-infected with HIV and tuberculosis. As of week 16, 723 suspected cases and 136 laboratory-confirmed cases of Mpox have been reported across 35 states and the Federal Capital Territory (FCT). The national case fatality rate currently stands at 2.2 per cent.

“The epidemic curve reveals multiple peaks in Mpox cases, indicating ongoing transmission. While most states have reported suspected cases, confirmed infections are heavily concentrated in Nigeria’s southern and central regions,” Dr. Idris noted.

To address these outbreaks, the NCDC has activated its Emergency Operations Centre (EOC), deployed National Rapid Response Teams to affected states, and prepositioned essential medical supplies, including personal protective equipment and laboratory consumables. Five additional Mpox diagnostic laboratories have also been optimized in Bauchi, Kano, Cross River, Rivers, and Enugu States.

“Healthcare workers are undergoing specialized training in infection prevention, case management, and cerebrospinal meningitis (CSM) care. Community outreach is being reinforced through public awareness campaigns, media engagement, and targeted health communication strategies,” he added.

On cerebrospinal meningitis, Dr. Idris reported a consistent decline in new cases and fatalities over the last three weeks.

He attributed the improvement to effective vaccination, early treatment, and adaptive surveillance strategies tailored to real-time data.

“Although the situation remains serious, strong national and state-level coordination is showing positive results. The response will continue until full containment is achieved and states take full ownership of the CSM Incident Action Plan,” he said.

Dr. Idris also expressed concern about the rising Mpox trend since its reemergence in 2017, with significant spikes recorded between 2022 and 2024, positioning Nigeria among the most affected countries globally. He warned that underreporting and delayed data entry remain challenges that need urgent resolution to ensure accurate and timely outbreak response.

A national mortality review for the recent Mpox deaths is being planned to further assess response effectiveness and identify areas for improvement.

The NCDC reaffirmed its commitment to safeguarding public health through timely surveillance, transparent reporting, and coordinated national response mechanisms aimed at reducing disease burden and preventing future outbreaks.